Core Viewpoint - Xtant Medical Holdings, Inc. has launched OsteoFactor Pro™, a new allogeneic growth factor solution aimed at enhancing bone healing and supporting surgical success in orthopedic and spine procedures [1][4]. Product Overview - OsteoFactor Pro™ is a naturally derived formulation rich in growth factors that enhances the biological activity and regenerative potential of orthobiologic scaffolds [2]. - The product features a biphasic release profile, providing an immediate bolus followed by sustained growth factor release, which stimulates key natural bone regeneration pathways such as angiogenesis, chemotaxis, and osteogenesis [2]. - It is an off-the-shelf, ready-to-use solution that integrates with various scaffolds, offering surgeons versatility and biologic performance for diverse bone regeneration approaches [3]. Company Positioning - With the launch of OsteoFactor Pro™, Xtant Medical becomes the first vertically integrated company to provide solutions across all five major orthobiologic categories, including demineralized bone matrix, cellular allografts, synthetics, structural allografts, and growth factors [5]. - The company emphasizes its commitment to innovation, scalability, and addressing the full spectrum of needs in regenerative medicine [5]. Company Mission - Xtant Medical's mission focuses on honoring the gift of donation to enhance patients' quality of life through a comprehensive portfolio of orthobiologics and spinal implant systems [6].

Core Insights - Xtant Medical Holdings, Inc. reported a positive net income of $58,000 for Q1 2025, a significant improvement from a net loss of $4.4 million in Q1 2024, indicating a turnaround in financial performance [4][9] - The company achieved an 18% year-over-year revenue growth, reaching $32.9 million, driven by increased sales in orthobiologics and licensing revenue [2][3] - Xtant Medical has raised its revenue guidance for the full year 2025 to between $127 million and $131 million, reflecting an expected growth of 8% to 12% [10] Financial Highlights - Revenue for Q1 2025 was $32.9 million, compared to $27.9 million in Q1 2024, marking an 18% increase [3][9] - Gross margin decreased slightly to 61.5% from 62.1% year-over-year, primarily due to charges for excess and obsolete inventory [3][9] - Operating expenses decreased to $19.2 million in Q1 2025 from $20.8 million in Q1 2024, mainly due to reduced compensation and commission expenses [4][9] Cash Flow and EBITDA - The company generated $1.3 million in operating cash flow in Q1 2025, a turnaround from cash used in operations of $5.8 million in the prior year [2][9] - Non-GAAP adjusted EBITDA for Q1 2025 was $3.0 million, compared to an adjusted EBITDA loss of $1.0 million in Q1 2024 [5][9] Product Development - Xtant Medical launched Trivium™, a next-generation demineralized bone matrix allograft, which is expected to enhance the company's orthobiologics portfolio and drive future growth [2][9] Corporate Developments - The company completed a secondary private sale of existing shares by OrbiMed Advisors LLC, enhancing corporate governance flexibility by terminating the investor rights agreement with OrbiMed [9]

Core Viewpoint - Xtant Medical Holdings, Inc. has launched Trivium™, a next-generation demineralized bone matrix allograft aimed at improving bone grafting procedures through advanced technology and design [1][4]. Product Features - Trivium is designed with intertwined structures and interconnected porosity to enhance cell attachment and tissue ingrowth, creating an optimal healing environment [2]. - The product features superior moldability and handling characteristics, allowing for precise placement in various surgical applications [2]. - Trivium is processed using the proprietary BacteRinse® method, which preserves native bone morphogenetic proteins (BMPs) to ensure the delivery of essential bioavailable growth factors for bone repair [3]. Company Commitment - The launch of Trivium reflects Xtant Medical's commitment to innovation in regenerative medicine, providing surgeons with a reliable solution for diverse surgical needs [4]. - The product is now available through the company's nationwide distribution network of independent agents [4]. Company Overview - Xtant Medical Holdings, Inc. focuses on the design, development, and commercialization of orthobiologics and spinal implant systems, aiming to facilitate spinal fusion in complex procedures [5].